- CAS#
- 2381089-83-2
- Formula
- C221H343N51O64
- M.W.
- 4,731.40 g/mol
Retatrutida
Triple GIP/GLP-1/Glucagon agonist · Metabolism
Save up to 20% by volume
| Qty | Per unit | Save |
|---|---|---|
| 2+ | MX$1,967.00 | −5% |
| 3+ | MX$1,863.00 | −10% |
| 5+ | MX$1,760.00 | −15% |
| 10+ | MX$1,656.00 | −20% |
Retatrutida 10 mg (LY3437943) is a lyophilized research compound — a synthetic 39-modified-amino-acid peptide with identity confirmed by mass spectrometry and ≥99% purity verified by HPLC. Every batch ships with a traceable CoA.
- Lot
- RETA-2026-A01
- Purity
- ≥99.2%
- Expires
- 2027-03
Technical specifications
Download CoA (PDF) ↓- Molecular weight
- ~4,731 Da
- Sequence
- Synthetic peptide of 39 modified amino acids
- Format
- Sterile lyophilized
- Content
- 10 mg per vial
- Purity
- ≥99% verified by HPLC in batch CoA
- Identity
- Confirmed by mass spectrometry (MS)
- Storage
- Batch traceability and thermal chain documentation
- Endotoxins (LAL)
- < 5 EU/mg
- Water content (Karl Fischer)
- < 6%
- Amino acid analysis
- Composition confirmed by acid hydrolysis
About Retatrutida 10 mg
Retatrutida (LY3437943) is a synthetic 39-amino-acid peptide designed as a triple agonist at the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and Glucagon receptors. Identity and purity are verified by mass spectrometry and reverse-phase HPLC, with individual results reported in the Certificate of Analysis (CoA) for each batch.
Initial characterization of the compound was published by Coskun and colleagues in Cell Metabolism (2022) [1], and preclinical data from the research program are registered in peer-reviewed scientific literature and the public trials registry [2].
MX-1 Labs distributes Retatrutida 10 mg in Mexico as a scientific research compound with laboratory packaging, an auditable batch number, and complete per-vial analytical documentation. The product is intended exclusively for in vitro laboratory research; it is not a medication, supplement, or consumer product.
Research applications
Retatrutida acts simultaneously on three well-characterized G protein-coupled receptors in endocrinological literature: GIP, GLP-1, and the Glucagon receptor [1]. In preclinical models, combined activation of the first two is associated with effects on satiety, insulin sensitivity, and energy expenditure, while the glucagon component distinguishes Retatrutida from classical dual agonists by engaging hepatic lipolysis as an additional mechanism. The peptide structure includes non-canonical amino acid modifications and conjugation with a fatty acid to extend the plasma half-life observed in pharmacokinetic studies. The specific experimental application is the responsibility of the receiving lab and its authorized institutional SOP.
Storage and handling
Sealed vial: store protected from light, humidity, and prolonged air exposure per the batch documentation. Once the experimental solution is prepared, keep refrigerated under documented conditions when the lab protocol requires it; record the preparation date, diluent used, and workstation conditions. Stability of the prepared solution depends on the batch-specific CoA, the diluent, aseptic technique, and the research protocol. Discard the material at any sign of turbidity, suspended particles, or any color change from the initial observation.
Scientific references
- Coskun T et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metabolism 2022; 34(9):1234–1247. View source on PubMed →
- ClinicalTrials.gov — Registered studies for the clinical development of retatrutida. View registry →
Frequently asked questions
What's included in the Retatrutida 10 mg vial?+
A sterile lyophilized vial containing Retatrutida 10 mg (LY3437943, synthetic peptide of 39 modified amino acids), shipped with the batch-specific Certificate of Analysis (CoA) — the batch number on the vial is auditable against the independent analytical lab.
What purity is guaranteed?+
≥99% verified by reverse-phase HPLC with a full chromatogram in the CoA. Identity is confirmed by mass spectrometry, and endotoxin (LAL), water content (Karl Fischer), and amino-acid profile controls are also reported.
What makes Retatrutida unique compared to other incretin agonists?+
It is a triple agonist at GIP, GLP-1, and the Glucagon receptor. Initial characterization was published by Coskun and colleagues in Cell Metabolism (2022); the glucagon component distinguishes it from classical dual agonists in preclinical metabolic research programs.
How should the sealed vial be stored?+
Store protected from light, humidity, and prolonged air exposure per the batch documentation. Stability of the prepared solution depends on the batch-specific CoA, the diluent, aseptic technique, and the lab's institutional SOP.
Is it legal in Mexico?+
Yes, as a scientific research compound for experimental in vitro use. It is not a medication, supplement, or consumer product, and it is not approved by COFEPRIS for those uses.
How long does shipping take, and is there free shipping?+
1–4 business days depending on destination within Mexico (1–2 north, 2–3 center, 3–4 south) via Estafeta, FedEx, or DHL. Free shipping on orders over $2,500 MXN. We do not ship internationally.